IOL Chemicals & Pharmaceuticals Ltd
IOLCPIOL Chemicals & Pharmaceuticals Ltd's price has outrun its earnings. +61.6% in a year against EPS +36.3% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +61.6% in a year while annual EPS moved +36.3% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (10 weeks in) while the P/E sits at the 99th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +71.0% year on year, and 183% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
IOL Chemicals & Pharmaceuticals Ltd trades at ₹148, in a confirmed uptrend and 10 weeks into that stage. That is +42.3% against its own 200-day average. It sits at 78% of a 52-week range of ₹69 to ₹171. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 21 straight weeks.
Today the stock is in a confirmed uptrend — week 10 of stage 2, confirmed. At ₹148 it trades +42.3% versus its 200-day average and sits at 78% of its 52-week range (₹69–₹171).
Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +960% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 21 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 99th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
IOL Chemicals & Pharmaceuticals Ltd trades at 30.0× P/E, about the priciest it has ever traded. Its long-run median P/E is 18.5×, measured across 4.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 30.0× is about the priciest it has ever traded, against a long-run median of 18.5× measured over 4.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +36.3% against a +61.6% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +26.1%/yr price move, ~+1.6%/yr came from earnings growth and ~+24.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
IOL Chemicals & Pharmaceuticals Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −42.2% at the trough to +36.6%, a 5-quarter improving streak, ROCE holding at 10.8%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +11.5% | +1.5% | — | — |
| Profit | +36.6% | −0.2% | — | — |
| EPS | +36.3% | −0.4% | — | — |
| Share price | +61.6% | +26.1% | +2.3% | +17.3% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
71.1/100 — rank 4 of 24 in Pharma - API & CRAMS · 96% evidence confidence
IOL Chemicals & Pharmaceuticals Ltd scores 71.1 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 4. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 24.5 + 14.2 + 13.2 + 19.2 = 71.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
IOL Chemicals & Pharmaceuticals Ltd reported ₹619 Cr of revenue in the Mar 26 quarter, +17.2% year on year. That is the 6th straight quarter of year-on-year growth. Over 4 years it has compounded at 1.5% a year. The last full year, FY26, came in at ₹2,319 Cr. The last four reported quarters add to ₹2,319 Cr.
IOL Chemicals & Pharmaceuticals Ltd reported ₹619 Cr of revenue in the Mar 26 quarter, +17.2% year on year. That is the 6th straight quarter of year-on-year growth. Over 4 years it has compounded at 1.5% a year. The last full year, FY26, came in at ₹2,319 Cr. The last four reported quarters add to ₹2,319 Cr.
FY26 revenue came in at ₹2,319 Cr (+11.5% on the year), capping 4 years at 1.5% compound. The latest quarter (Mar 26) printed ₹619 Cr, +17.2% year on year — the 6th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +11.5% growth against the decade's 1.5% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +11.5% over the last 4 quarters against +4.3%/yr over the last 8 — accelerating; TTM profit +36.6% vs +1.1%/yr — accelerating.
→ Revenue grew — did margins hold as it scaled? Next: 15.0% this quarter (+3.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
IOL Chemicals & Pharmaceuticals Ltd's operating margin is 15.0% in the Mar 26 quarter, +3.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 10.0% to 12.0%.
IOL Chemicals & Pharmaceuticals Ltd's operating margin is 15.0% in the Mar 26 quarter, +3.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 10.0% to 12.0%.
The latest quarter's operating margin is 15.0%, +3.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 10.0%–12.0%, and FY26's 12.0% is the top of that band — a record year.
Why the margin moved: operating margin went +3.0 pp year on year while gross margin went +5.4 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
→ Margins held — did that reach the bottom line? Next: profit +71.0% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
IOL Chemicals & Pharmaceuticals Ltd earned ₹53.0 Cr of net profit in the Mar 26 quarter, +71.0% year on year. Full-year FY26 profit was ₹138 Cr. The 4-year compound rate is −4.8%. That is 8.6% of the quarter's revenue. The same quarter a year earlier earned ₹31.0 Cr.
IOL Chemicals & Pharmaceuticals Ltd earned ₹53.0 Cr of net profit in the Mar 26 quarter, +71.0% year on year. Full-year FY26 profit was ₹138 Cr. The 4-year compound rate is −4.8%. That is 8.6% of the quarter's revenue. The same quarter a year earlier earned ₹31.0 Cr.
Mar 26 profit was ₹53.0 Cr, +71.0% year on year. On the full year, FY26 printed ₹138 Cr (+36.6%), and the 4-year compound rate is −4.8%.
Why profit moved: revenue contributed +17.2% and the margin +3.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +35.5% vs revenue +11.5%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 183% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 183% of IOL Chemicals & Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹214 Cr of operating cash against ₹138 Cr of profit. After ₹165 Cr of capital spending, ₹49.0 Cr was left as free cash.
FY26: operating cash of ₹214 Cr against reported profit of ₹138 Cr, leaving free cash of ₹49.0 Cr after ₹165 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 183% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 183%: the cash cycle tightened 11 days between FY22 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 3.0× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹651 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
IOL Chemicals & Pharmaceuticals Ltd's cash conversion cycle runs 68 days in FY26, down from 79 days in FY22. Capital spending ran ₹651 Cr over the last 3 years. At FY26 sales of ₹2,319 Cr each day of that cycle holds about ₹6.4 Cr, so roughly ₹432 Cr sits inside the business at any moment.
FY26: debtors at 95 days, inventory at 91 days — roughly 3.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 68 days, tighter than FY22's 79.
The full loop: cash goes out to suppliers and production on day 0; stock waits 91 days to sell; customers pay about 95 days after that; and suppliers themselves are paid at 118 days — netting out to the 68-day cycle.
In money terms: at FY26 sales of ₹2,319 Cr, each day of the cycle holds about ₹6.4 Cr — so the 68-day loop keeps roughly ₹432 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹651 Cr over the last 3 fiscal years against ₹215 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹94.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 11% and the ROIC − WACC spread is −3.9 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
IOL Chemicals & Pharmaceuticals Ltd earns a ROCE of 11% in FY26. That is up from a trough of 9% in FY25. Return on invested capital clears the cost of that capital by −3.9 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 6.0% net margin on 0.90× asset turns.
FY26 ROCE is 11%, recovered from a FY25 trough of 9% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 6.0% net margin × 0.90× asset turns × 1.44× balance-sheet leverage ≈ 7.8% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 8.1% − 12.0% = a −3.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.08.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
IOL Chemicals & Pharmaceuticals Ltd carries total debt of ₹135 Cr against shareholder equity of ₹1,799 Cr as of Mar 26, a debt-to-equity of 0.08 — effectively unlevered. On the annual view that ratio went from 0.03 in FY22 to 0.08 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹135 Cr against shareholder equity of ₹1,799 Cr — a debt-to-equity of 0.08. On the annual view, debt-to-equity went from 0.03 (FY22) to 0.08 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: Promoters added 14.1 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters added 14.1 points of IOL Chemicals & Pharmaceuticals Ltd over 8 quarters, the biggest move on the register. That takes promoters to 62.3% of the company. Foreign institutions moved +3.5 points over the same window, to 4.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +14.1 points over 8 quarters to 62.3%; Foreign institutions: +3.5 points over 8 quarters to 4.9%; Domestic institutions: +0.3 points over 8 quarters to 0.4%.
Why the register moved: promoters drove it (+14.1 points), alongside foreign institutions (+3.5 points) — steady accumulation by institutions reading the same numbers this page reads.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
IOL Chemicals & Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| IOL Chemicals & Pharmaceuticals Ltd this page | 30.0× | ₹4,380 Cr | Improving | |||
| Divis Laboratories Ltd | 73.4× | ₹1.9L Cr | Mixed | |||
| Laurus Labs Ltd | 79.1× | ₹86,505 Cr | Mixed | |||
| Anthem Biosciences Ltd | 73.1× | ₹43,360 Cr | No read | |||
| Gland Pharma Ltd | 37.6× | ₹39,257 Cr | Improving | |||
| Acutaas Chemicals Ltd | 75.2× | ₹26,785 Cr | Improving | |||
| Acutaas Chemicals Ltd | 69.1× | ₹26,686 Cr | Mixed | |||
| Sai Life Sciences Ltd | 73.8× | ₹26,174 Cr | No read | |||
| Piramal Pharma Ltd | — | ₹24,133 Cr | No read | |||
| Neuland Laboratories Ltd | 65.9× | ₹23,794 Cr | Turning around | |||
| Granules India Ltd | 31.8× | ₹20,655 Cr | Consistent | |||
| OneSource Specialty Pharma Ltd | — | ₹18,961 Cr | No read | |||
| Syngene International Ltd | 44.9× | ₹16,708 Cr | Turning around | |||
| Syngene International Ltd | 44.1× | ₹16,415 Cr | Turning around | |||
| Cohance Lifesciences Ltd | 80.9× | ₹15,957 Cr | Deteriorating | |||
| Jubilant Pharmova Ltd | 35.2× | ₹15,378 Cr | No read | |||
| Concord Biotech Ltd | 54.8× | ₹13,061 Cr | Deteriorating | |||
| Shilpa Medicare Ltd | 50.8× | ₹11,856 Cr | No read | |||
| Blue Jet Healthcare Ltd | 43.3× | ₹10,730 Cr | Deteriorating | |||
| Supriya Lifescience Ltd | 32.3× | ₹6,765 Cr | Consistent | |||
| SMS Pharmaceuticals Ltd | 35.0× | ₹3,569 Cr | Mixed | |||
| Morepen Laboratories Ltd | 39.6× | ₹2,948 Cr | Mixed | |||
| Dishman Carbogen Amcis Ltd | 29.0× | ₹2,878 Cr | No read | |||
| Hikal Ltd | 73.8× | ₹2,681 Cr | Deteriorating | |||
| Solara Active Pharma Sciences Ltd | 551.0× | ₹2,351 Cr | No read | |||
| Windlas Biotech Ltd | 26.6× | ₹1,770 Cr | Mixed |
Frequently asked questions
What is IOL Chemicals & Pharmaceuticals Ltd's share price today?
IOL Chemicals & Pharmaceuticals Ltd trades at ₹148, +61.6% over the past year. The company is valued at ₹4,380 Cr. The stock sits at 78% of its 52-week range of ₹69–₹171, +42.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 10 weeks in. — as of 24 July 2026.
What were IOL Chemicals & Pharmaceuticals Ltd's latest quarterly results?
IOL Chemicals & Pharmaceuticals Ltd reported revenue of ₹619 Cr and net profit of ₹53.0 Cr for the Mar 26 quarter. Revenue rose 17.2% and profit rose 71.0% year on year. Earnings per share were ₹1.81. The operating margin was 15.0%, 3.0 pp higher than a year earlier. — as of 24 July 2026.
What is IOL Chemicals & Pharmaceuticals Ltd's revenue?
IOL Chemicals & Pharmaceuticals Ltd reported revenue of ₹619 Cr in the Mar 26 quarter, +17.2% year on year. For the full FY26 fiscal year, revenue was ₹2,319 Cr (+11.5%). Over the last 4 years revenue compounded at 1.5% a year. — as of 24 July 2026.
What is IOL Chemicals & Pharmaceuticals Ltd's profit?
IOL Chemicals & Pharmaceuticals Ltd earned ₹53.0 Cr of net profit in the Mar 26 quarter, +71.0% year on year. Full-year FY26 profit was ₹138 Cr. The operating margin ran 15.0% in the latest quarter. — as of 24 July 2026.
What is IOL Chemicals & Pharmaceuticals Ltd's market cap?
IOL Chemicals & Pharmaceuticals Ltd's market capitalisation is ₹4,380 Cr at a share price of ₹148. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is IOL Chemicals & Pharmaceuticals Ltd's P/E ratio?
IOL Chemicals & Pharmaceuticals Ltd trades at a P/E of 30.0×, at the 99th percentile of its own 4-year range, against a long-run median of 18.5×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does IOL Chemicals & Pharmaceuticals Ltd pay a dividend?
Yes — IOL Chemicals & Pharmaceuticals Ltd's dividend payout was 21% of profit in FY26, and it recorded a payout in each of its last 5 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is IOL Chemicals & Pharmaceuticals Ltd overvalued?
On its own history, IOL Chemicals & Pharmaceuticals Ltd looks expensive against its own history: its P/E of 30.0× sits at the 99th percentile of its 4-year range (long-run median 18.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 24 July 2026.
Is IOL Chemicals & Pharmaceuticals Ltd growing?
Yes — IOL Chemicals & Pharmaceuticals Ltd is growing: latest-quarter revenue +17.2% year on year, profit +71.0%, and the margin +3.0 pp at 15.0%. The 4-year compound rates are 1.5% (revenue) and −4.8% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is IOL Chemicals & Pharmaceuticals Ltd performing?
IOL Chemicals & Pharmaceuticals Ltd is in a confirmed uptrend, 10 weeks in. Its latest quarter's revenue rose 17.2% and profit rose 71.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 21 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is IOL Chemicals & Pharmaceuticals Ltd in?
Turning around — profit growth swung from −42.2% at the trough to +36.6%, a 5-quarter improving streak, ROCE holding at 10.8%. The read comes from the last 12 quarters of growth (revenue growth +11.5% latest, profit growth +36.6% latest, eps growth +36.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is IOL Chemicals & Pharmaceuticals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 10 of stage 2), trading +42.3% versus its 200-day average and at 78% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is IOL Chemicals & Pharmaceuticals Ltd beating the market?
On recent form, yes — IOL Chemicals & Pharmaceuticals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 21 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.3 years the stock moved +960% against the NIFTY 500's +274% — ahead of the index over the full window. — as of 24 July 2026.
Will IOL Chemicals & Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for IOL Chemicals & Pharmaceuticals Ltd. What it measures instead: the share price is ₹148, the price is in a confirmed uptrend 10 weeks in. Its P/E of 30.0× sits at the 99th percentile of its own 4-year range. — as of 24 July 2026.
Who owns IOL Chemicals & Pharmaceuticals Ltd?
Promoters hold 62.3% of IOL Chemicals & Pharmaceuticals Ltd, foreign institutions 4.9%, domestic institutions 0.4% and the public 32.4% (latest quarter). The biggest move on the register over the last two years: Promoters added 14.1 points over 8 quarters. — as of 24 July 2026.
Does IOL Chemicals & Pharmaceuticals Ltd have too much debt?
No — IOL Chemicals & Pharmaceuticals Ltd's debt-to-equity is 0.08, and operating profit covers the interest bill 18×. FY26 borrowings were ₹135 Cr against equity of ₹1,799 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is IOL Chemicals & Pharmaceuticals Ltd's capex?
IOL Chemicals & Pharmaceuticals Ltd spent ₹651 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹165 Cr, with ₹94.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is IOL Chemicals & Pharmaceuticals Ltd's cash flow?
IOL Chemicals & Pharmaceuticals Ltd generated ₹214 Cr of operating cash flow in FY26 and ₹49.0 Cr of free cash flow after ₹165 Cr of capital spending. Reported profit that year was ₹138 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is IOL Chemicals & Pharmaceuticals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 183% of IOL Chemicals & Pharmaceuticals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹214 Cr against reported profit of ₹138 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is IOL Chemicals & Pharmaceuticals Ltd in its business cycle?
IOL Chemicals & Pharmaceuticals Ltd's FY26 operating margin was 12.0%, against a 5-year band of 10.0%–12.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 15.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the IOL Chemicals & Pharmaceuticals Ltd story?
The sharpest disagreement: the price moved +61.6% in a year while annual EPS moved +36.3% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is IOL Chemicals & Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: IOL Chemicals & Pharmaceuticals Ltd's price has outrun its earnings. +61.6% in a year against EPS +36.3% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.